Loading…
Fostering Innovation Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Fostering Innovation Act of 2019 This bill establishes a temporary exemption from the requirement that each registered public accounting firm that prepares or issues an audit report for an issuer of securities (other than an emerging growth company) shall attest to, and report on, the internal control assessment made by the management of the issuer. Specifically, this requirement shall not apply with respect to an audit report prepared for an issuer that ceased to be an emerging growth company on the last day of its fiscal year following the five-year period beginning on the date of its first sale of common equity securities, had average annual gross revenues of less than $50 million as of its most recently completed fiscal year, and is not a large accelerated filer. An issuer shall cease to be eligible for the exemption at the earliest of (1) the last day of the fiscal year following the 10-year period beginning on the date of its first sale of common equity securities, (2) the last day of the fiscal year in which its average annual gross revenues exceed $50 million, or (3) when the issuer becomes a large accelerated filer.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2020 · second_quarter · Small Business
Capital Market Enhancements ---Accredited Investor Definition ---Amended Definition of Smaller Reporting Company ---Encouraging Employee Ownership Act ---SEC Rule 701 ---SEC Small Business Forum ---Small Business Capital Formation Enhancement Act Coronavirus (COVID-19) Pandemic ---NOL Monetization ---Pause on Graduating from ECG Status (ECG Pause) ---Small Business Loans ---R&D Credit Temporary Refundability Coronavirus (COVID-19) Small Business Loans (Non-Funding) ---H.R.266: Paycheck Protection Program and Health Care Enhancement Act of 2020 ---Affiliation ---CARES Act Payroll Protection Loan Program Implementation ---Eligibility ---Payroll Tax Deferral Funding for Coronavirus (COVID-19) Small Business Loans --- H.R.266: Paycheck Protection Program and Health Care Enhancement Act Proxy Advisory Services ---Impact of Policies on Small Public Companies Sarbanes Oxley Section 404 (b) ---H.R.3886/S.452: Fostering Innovation Act of 2019 ---Small Issuer Exemption Small Business Innovation Research (SBIR) Program
Referred to the House Committee on Financial Services.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $3,320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of
2020 · second_quarter · Small Business
Capital Market Enhancements ---Accredited Investor Definition ---Amended Definition of Smaller Reporting Company ---Encouraging Employee Ownership Act ---SEC Rule 701 ---SEC Small Business Forum ---Small Business Capital Formation Enhancement Act Coronavirus (COVID-19) Pandemic ---NOL Monetization ---Pause on Graduating from ECG Status (ECG Pause) ---Small Business Loans ---R&D Credit Temporary Refundability Coronavirus (COVID-19) Small Business Loans (Non-Funding) ---H.R.266: Paycheck Protection Program and Health Care Enhancement Act of 2020 ---Affiliation ---CARES Act Payroll Protection Loan Program Implementation ---Eligibility ---Payroll Tax Deferral Funding for Coronavirus (COVID-19) Small Business Loans --- H.R.266: Paycheck Protection Program and Health Care Enhancement Act Proxy Advisory Services ---Impact of Policies on Small Public Companies Sarbanes Oxley Section 404 (b) ---H.R.3886/S.452: Fostering Innovation Act of 2019 ---Small Issuer Exemption Small Business Innovation Research (SBIR) Program
Client expense: $3,320,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · fourth_quarter · Banking
Small company capital formation issues; capital markets reform to encourage more IPOs, including disclosure of material short positions, venture exchanges, issues related to shareholder proposals, improving research coverage for small companies; Dodd-Frank regulatory issues including: revising the definition of venture capital fund for purposes of fund registration, Volcker Rule; blockchain regulatory and policy issues, including the Token Taxonomy Act H.R. 2144 and FinCEN rule regarding convertible virtual currencies; Implementation of the Foreign Investment Risk Review Modernization Act (FIRRMA); Developing and Empowering our Aspiring Leaders (DEAL) Act H.R. 8603; Fostering Innovation Act S. 452, H.R. 3886; Amendment to Accelerated Filer and Large Accelerated Filer definition; Beneficial ownership legislation including Corporate Transparency Act, H.R. 2513/S. 1978 and Illicit Cash Act, S. 2563; Private Securities Transparency and Reform Act; Managed Stablecoins are Securities Act H.R. 5197; Helping Startups Continue to Grow Act HR 4918; SEC proposal to modernize advertising and cash solicitation rules; Issues related to Coronavirus Aid, Relief, and Economic Security Act; Main Street Loan Program.
Client expense: $847,156 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Defense, Dept of (DOD), Federal Communications Commission (FCC), Federal Reserve System, Financial Crimes Enforcement Network (FinCEN), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, White House Office
2020 · fourth_quarter · Small Business
Capital Formation Incentives ---H.R.7505: American Innovation Act of 2020 ---H.R.7537: Infectious Disease Therapies Research and Innovation Act ---H.R.7555: The More Cures Act of 2020 ---H.R.7556: Start-Ups for Cures Act ---H.R.7917: IGNITE American Innovation Act ---S.1249: American Innovation Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---Introduction of IGNITE American Innovation Act in Senate ---Proposed amendments under the Exchange Act of 1934 ---Proposed amendments under the Investment Company Act of 1940 ---Proposed amendments under the Securities Act of 1933 ---Reform of Net Operating Loss Rules Capital Market Enhancements ---Amended Definition of Smaller Reporting Company Coronavirus (COVID-19) Pandemic ---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020 ---H.R.7917: IGNITE American Innovation Act ---Introduction of IGNITE American Innovation Act in Senate Coronavirus (COVID-19) Small Business Loans (Non-Funding) ---Affiliation ---Eligibility ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Sarbanes Oxley Section 404 (b) ---H.R.3886/S.452: Fostering Innovation Act of 2019 ---Implementation of Jumpstart Our Business Startups (JOBS) Act of 2012 Small Business Innovation Research (SBIR) Program
Client expense: $3,180,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2020 · fourth_quarter · Financial Institutions/Investments/Securities
Issues related to capital formation and capital markets; JOBS Act expansion; market structure; S. 452, H.R. 3886 - Fostering Innovation Act; issues related to smaller reporting companies; SEC Form 13F proposals and changes to the definition of accredited investor.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2020 · third_quarter · Small Business
Capital Formation Incentives ---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020 ---Incentives for Sustainable Aviation Fuels ---H.R.7537: Infectious Disease Therapies Research and Innovation Act ---H.R.7556: To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. ---H.R.7555: To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities. H.R.7537: Infectious Disease Therapies Research and Innovation Act H.R.7505: American Innovation Act Capital Market Enhancements ---Accredited Investor Definition ---Amended Definition of Smaller Reporting Company ---Encouraging Employee Ownership Act ---SEC Rule 701 ---SEC Small Business Forum ---Small Business Capital Formation Enhancement Act Coronavirus (COVID-19) Pandemic ---H.R.7917 IGNITE American Innovation Act ---H.R.7661: Covid ECG Extension Act ---H.R. 7917 IGNITE American Innovation Act ---Small Business Loans ---R&D Credit Temporary Refundability Coronavirus (COVID-19) Small Business Loans (Non-Funding) ---H.R.266: Paycheck Protection Program and Health Care Enhancement Act of 2020 ---S.4775: The Delivering Immediate Relief to America's Families, Schools and Small Business Act ---Affiliation ---CARES Act Payroll Protection Loan Program Implementation ---Eligibility ---Payroll Tax Deferral Funding for Coronavirus (COVID-19) Small Business Loans --- H.R.266: Paycheck Protection Program and Health Care Enhancement Act Proxy Advisory Services ---Impact of Policies on Small Public Companies Sarbanes Oxley Section 404 (b) ---H.R.3886/S.452: Fostering Innovation Act of 2019 ---Small Issuer Exemption Small Business Innovation Research (SBIR) Program
2020 · third_quarter · Financial Institutions/Investments/Securities
Issues related to capital formation and capital markets; JOBS Act expansion; market structure; S. 452, H.R. 3886 - Fostering Innovation Act; issues related to smaller reporting companies; SEC Form 13F reforms and changes to the definition of accredited investor.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2020 · third_quarter · Banking
Small company capital formation issues; capital markets reform to encourage more IPOs, including disclosure of material short positions, venture exchanges, issues related to shareholder proposals, improving research coverage for small companies; Dodd-Frank regulatory issues including: revising the definition of venture capital fund for purposes of fund registration, Volcker Rule; blockchain regulatory and policy issues, including the Token Taxonomy Act H.R. 2144; Implementation of the Foreign Investment Risk Review Modernization Act (FIRRMA); Developing and Empowering our Aspiring Leaders (DEAL) Act; Fostering Innovation Act S. 452, H.R. 3886; Amendment to Accelerated Filer and Large Accelerated Filer definition; Beneficial ownership legislation including Corporate Transparency Act, H.R. 2513/S. 1978 and Illicit Cash Act, S. 2563; Private Securities Transparency and Reform Act; Managed Stablecoins are Securities Act H.R. 5197; Helping Startups Continue to Grow Act HR 4918; SEC proposal to modernize advertising and cash solicitation rules; Issues related to Coronavirus Aid, Relief, and Economic Security Act; Main Street Loan Program.
Client expense: $588,387 · Firm income: Not reported
2020 · second_quarter · Banking
Small company capital formation issues; capital markets reform to encourage more IPOs, including disclosure of material short positions, venture exchanges, issues related to shareholder proposals, improving research coverage for small companies; Dodd-Frank regulatory issues including: revising the definition of venture capital fund for purposes of fund registration, Volcker Rule; blockchain regulatory and policy issues, including the Token Taxonomy Act H.R. 2144; Implementation of the Foreign Investment Risk Review Modernization Act (FIRRMA); Developing and Empowering our Aspiring Leaders (DEAL) Act; Fostering Innovation Act S. 452, H.R. 3886; Amendment to Accelerated Filer and Large Accelerated Filer definition; Beneficial ownership legislation including Corporate Transparency Act, H.R. 2513/S. 1978 and Illicit Cash Act, S. 2563; Private Securities Transparency and Reform Act; Managed Stablecoins are Securities Act H.R. 5197; Helping Startups Continue to Grow Act HR 4918; SEC proposal to modernize advertising and cash solicitation rules; Issues related to Coronavirus Aid, Relief, and Economic Security Act; Request to temporarily waive notarization requirements for Form ID filings during COVID-19 crisis; Request to allow flexibility in custody rule during COVID-19 crisis; Main Street Loan Program.
Client expense: $609,952 · Firm income: Not reported
2020 · second_quarter · Small Business
Capital Market Enhancements ---Accredited Investor Definition ---Amended Definition of Smaller Reporting Company ---Encouraging Employee Ownership Act ---SEC Rule 701 ---SEC Small Business Forum ---Small Business Capital Formation Enhancement Act Coronavirus (COVID-19) Pandemic ---NOL Monetization ---Pause on Graduating from ECG Status (ECG Pause) ---Small Business Loans ---R&D Credit Temporary Refundability Coronavirus (COVID-19) Small Business Loans (Non-Funding) ---H.R.266: Paycheck Protection Program and Health Care Enhancement Act of 2020 ---Affiliation ---CARES Act Payroll Protection Loan Program Implementation ---Eligibility ---Payroll Tax Deferral Funding for Coronavirus (COVID-19) Small Business Loans --- H.R.266: Paycheck Protection Program and Health Care Enhancement Act Proxy Advisory Services ---Impact of Policies on Small Public Companies Sarbanes Oxley Section 404 (b) ---H.R.3886/S.452: Fostering Innovation Act of 2019 ---Small Issuer Exemption Small Business Innovation Research (SBIR) Program
Client expense: $3,320,000 · Firm income: Not reported
2020 · second_quarter · Financial Institutions/Investments/Securities
Issues related to capital formation and capital markets; JOBS Act expansion; market structure; S 452, HR 3886 - Fostering Innovation Act; issues related to smaller reporting companies; short selling transparency
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Small Business
Capital Market Enhancements ---Accredited Investor Definition ---Amended Definition of Smaller Reporting Company Coronavirus (COVID-19) Small Business Loans (Non-Funding) ---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Affiliation ---Eligibility Funding for Coronavirus (COVID-19) Small Business Loans ---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Proxy Advisory Services ---H.R.4015: Corporate Governance Reform and Transparency Act of 2017 ---S.3614: Corporate Governance Fairness Act of 2018 ---Impact of Policies on Small Public Companies Sarbanes Oxley Section 404 (b) ---H.R.3886/S.452: Fostering Innovation Act of 2019 ---Small Issuer Exemption Short Selling Transparency Small Business Innovation Research (SBIR) Program
Client expense: $2,890,000 · Firm income: Not reported
2020 · first_quarter · Financial Institutions/Investments/Securities
Issues related to capital formation and capital markets; JOBS Act expansion; market structure; S 452, HR 3886 - Fostering Innovation Act; issues related to smaller reporting companies; short selling transparency
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Banking
Small company capital formation issues; capital markets reform to encourage more IPOs, including disclosure of material short positions, venture exchanges, issues related to shareholder proposals, improving research coverage for small companies; Dodd-Frank regulatory issues including: revising the definition of venture capital fund for purposes of fund registration, Volcker Rule; blockchain regulatory and policy issues, including the Token Taxonomy Act H.R. 2144; Implementation of the Foreign Investment Risk Review Modernization Act (FIRRMA); Developing and Empowering our Aspiring Leaders (DEAL) Act; Fostering Innovation Act S. 452, H.R. 3886; Amendment to Accelerated Filer and Large Accelerated Filer definition; Beneficial ownership legislation including Corporate Transparency Act, H.R. 2513/S. 1978 and Illicit Cash Act, S. 2563; Private Securities Transparency and Reform Act; Managed Stablecoins are Securities Act H.R. 5197; Helping Startups Continue to Grow Act HR 4918; SEC proposal to modernize advertising and cash solicitation rules; Issues related to Coronavirus Aid, Relief, and Economic Security Act; Request to temporarily waive notarization requirements for Form ID filings during COVID-19 crisis; Request to allow flexibility in custody rule during COVID-19 crisis
Client expense: $569,176 · Firm income: Not reported
2019 · fourth_quarter · Banking
Small company capital formation issues; capital markets reform to encourage more IPOs, including disclosure of material short positions, venture exchanges, issues related to shareholder proposals, improving research coverage for small companies; Dodd-Frank regulatory issues including: revising the definition of venture capital fund for purposes of fund registration, Volcker Rule; blockchain regulatory and policy issues, including the Token Taxonomy Act H.R. 2144; Implementation of the Foreign Investment Risk Review Modernization Act (FIRRMA); Developing and Empowering our Aspiring Leaders (DEAL) Act; Fostering Innovation Act S. 452, H.R. 3886; Amendment to Accelerated Filer and Large Accelerated Filer definition; Beneficial ownership legislation including Corporate Transparency Act, H.R. 2513/S. 1978 and Illicit Cash Act, S. 2563; Private Securities Transparency and Reform Act; Managed Stablecoins are Securities Act H.R. 5197; Helping Startups Continue to Grow Act HR 4918
Client expense: $775,933 · Firm income: Not reported
2019 · fourth_quarter · Financial Institutions/Investments/Securities
Issues related to capital formation and capital markets; implementation of the JOBS Act; market structure; S452, HR 3886 Fostering Innovation Act; issues related to smaller reporting companies; short selling transparency
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Banking
Small company capital formation issues; capital markets reform to encourage more IPOs, including disclosure of material short positions, venture exchanges, issues related to shareholder proposals, improving research coverage for small companies; Dodd-Frank regulatory issues including: revising the definition of venture capital fund for purposes of fund registration, Volcker Rule; blockchain regulatory and policy issues, including the Token Taxonomy Act H.R. 2144; Implementation of the Foreign Investment Risk Review Modernization Act (FIRRMA); Developing and Empowering our Aspiring Leaders (DEAL) Act; Fostering Innovation Act S. 452, H.R. 3886; Amendment to Accelerated Filer and Large Accelerated Filer definition; Beneficial ownership legislation including Corporate Transparency Act, H.R. 2513/S. 1978 and Illicit Cash Act, S. 2563; Private Securities Transparency and Reform Act
Client expense: $670,103 · Firm income: Not reported
2019 · third_quarter · Financial Institutions/Investments/Securities
Issues related to capital formation and capital markets; implementation of the JOBS Act; market structure; S452, HR 3886 Fostering Innovation Act; issues related to smaller reporting companies; short selling transparency
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $3,170,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Defense, Dept of (DOD), Federal Communications Commission (FCC), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Defense, Dept of (DOD), Federal Communications Commission (FCC), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Council of Economic Advisers (CEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Defense, Dept of (DOD), Federal Communications Commission (FCC), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Defense, Dept of (DOD), Federal Communications Commission (FCC), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Defense, Dept of (DOD), Federal Communications Commission (FCC), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury, Dept of, White House Office